Who are zanamivir for inhalation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): active oseltamivir, Oseltamivir phosphate granules, Oseltamivir Phosphate For Oral Suspension, Tamiflu®, Tamiflu (verum), Oseltamivir(oral).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zanamivir-for-inhalation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

zanamivir for inhalation — Competitive Intelligence Brief

zanamivir for inhalation (zanamivir for inhalation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuraminidase inhibitor. Area: Infectious Disease.

marketed Neuraminidase inhibitor Influenza neuraminidase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

zanamivir for inhalation (zanamivir for inhalation) — University of Oxford. Zanamivir inhibits neuraminidase, an enzyme on the surface of influenza viruses, preventing viral release from infected cells and blocking spread of infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
zanamivir for inhalation TARGET	zanamivir for inhalation	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase
active oseltamivir	active oseltamivir	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Oseltamivir phosphate granules	Oseltamivir phosphate granules	China Academy of Chinese Medical Sciences	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Oseltamivir Phosphate For Oral Suspension	Oseltamivir Phosphate For Oral Suspension	The Affiliated Hospital of Qingdao University	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Tamiflu®	Tamiflu®	Genuine Research Center, Egypt	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Tamiflu (verum)	Tamiflu (verum)	National Institute for Public Health and the Environment (RIVM)	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Oseltamivir(oral)	Oseltamivir(oral)	Guangdong Raynovent Biotech Co., Ltd	marketed	Neuraminidase inhibitor	Influenza neuraminidase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuraminidase inhibitor class)

University of Oxford · 2 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Guangdong Raynovent Biotech Co., Ltd · 2 drugs in this class
UMC Utrecht · 2 drugs in this class
Genuine Research Center, Egypt · 1 drug in this class
The First Affiliated Hospital of Guangzhou Medical University · 1 drug in this class
China Academy of Chinese Medical Sciences · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
National Institute for Public Health and the Environment (RIVM) · 1 drug in this class
The Affiliated Hospital of Qingdao University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). zanamivir for inhalation — Competitive Intelligence Brief. https://druglandscape.com/ci/zanamivir-for-inhalation. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab